Cover Image
市場調查報告書

IntelGenx Corp.:產品平台分析

IntelGenx Corp. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 204918
出版日期 內容資訊 英文 34 Pages
訂單完成後即時交付
價格
Back to Top
IntelGenx Corp.:產品平台分析 IntelGenx Corp. - Product Pipeline Review - 2015
出版日期: 2015年10月14日 內容資訊: 英文 34 Pages
簡介

IntelGenx Corp.是IntelGenx Technologies Corp.的子公司,是提供藥物遞輸技術的製藥公司。正在開發口服型速效型藥物和控制釋放製劑。有Forfivo、Rizatriptan film、Tadalafil film、INT0028、VetaFilm等產品。

本報告提供IntelGenx Corp.調查分析,提供您企業概要,研究·開發概要,開發平台分析,開發中產品的概要,藥物簡介,最新趨勢和計劃等相關的系統性資訊。

目錄

IntelGenx Corp.的概述

  • IntelGenx Corp.概要
  • 主要資訊
  • 企業資料

IntelGenx Corp.:研究·開發概要

  • 主要的治療領域

IntelGenx Corp.:開發平台分析

  • 各開發階段的開發中產品
  • 開發中產品:單獨療法
  • 開發中產品:合作夥伴產品
  • 開發中產品:轉出授權產品

IntelGenx Corp.:開發中產品的概要

  • 臨床階段的開發中產品
  • 初期階段的開發中產品

IntelGenx Corp.:藥物簡介

  • INT-0028
  • INT-0036
  • metoprolol succinate
  • tadalafil
  • INT-0031
  • INT-0037
  • INT-0039
  • INT-0029
  • INT-0035

IntelGenx Corp.:開發平台分析

  • 按開發中產品:標的
  • 開發中產品:各給藥途徑
  • 開發中產品:各分子類型
  • 開發中產品:各作用機制

IntelGenx Corp.:開發平台(管線)的最新趨勢

IntelGenx Corp.:暫停中的計劃

IntelGenx Corp.:所在地與子公司

  • 總公司

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07649CDB

Summary

Global Markets Direct's, 'IntelGenx Corp. - Product Pipeline Review - 2015', provides an overview of the IntelGenx Corp.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of IntelGenx Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of IntelGenx Corp. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of IntelGenx Corp.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the IntelGenx Corp.'s pipeline products

Reasons to buy

  • Evaluate IntelGenx Corp.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of IntelGenx Corp. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the IntelGenx Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of IntelGenx Corp. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of IntelGenx Corp.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of IntelGenx Corp. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • IntelGenx Corp. Snapshot
    • IntelGenx Corp. Overview
    • Key Information
    • Key Facts
  • IntelGenx Corp. - Research and Development Overview
    • Key Therapeutic Areas
  • IntelGenx Corp. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • IntelGenx Corp. - Pipeline Products Glance
    • IntelGenx Corp. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • IntelGenx Corp. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • IntelGenx Corp. - Drug Profiles
    • INT-0028
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INT-0036
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • metoprolol succinate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tadalafil
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INT-0031
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INT-0037
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INT-0039
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INT-0029
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INT-0035
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • IntelGenx Corp. - Pipeline Analysis
    • IntelGenx Corp. - Pipeline Products by Target
    • IntelGenx Corp. - Pipeline Products by Route of Administration
    • IntelGenx Corp. - Pipeline Products by Molecule Type
    • IntelGenx Corp. - Pipeline Products by Mechanism of Action
  • IntelGenx Corp. - Recent Pipeline Updates
  • IntelGenx Corp. - Dormant Projects
  • IntelGenx Corp. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • IntelGenx Corp., Key Information
  • IntelGenx Corp., Key Facts
  • IntelGenx Corp. - Pipeline by Indication, 2015
  • IntelGenx Corp. - Pipeline by Stage of Development, 2015
  • IntelGenx Corp. - Monotherapy Products in Pipeline, 2015
  • IntelGenx Corp. - Partnered Products in Pipeline, 2015
  • IntelGenx Corp. - Partnered Products/ Combination Treatment Modalities, 2015
  • IntelGenx Corp. - Out-Licensed Products in Pipeline, 2015
  • IntelGenx Corp. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • IntelGenx Corp. - Phase I, 2015
  • IntelGenx Corp. - Preclinical, 2015
  • IntelGenx Corp. - Discovery, 2015
  • IntelGenx Corp. - Pipeline by Target, 2015
  • IntelGenx Corp. - Pipeline by Route of Administration, 2015
  • IntelGenx Corp. - Pipeline by Molecule Type, 2015
  • IntelGenx Corp. - Pipeline Products by Mechanism of Action, 2015
  • IntelGenx Corp. - Recent Pipeline Updates, 2015
  • IntelGenx Corp. - Dormant Developmental Projects,2015

List of Figures

  • IntelGenx Corp. - Pipeline by Top 10 Indication, 2015
  • IntelGenx Corp. - Pipeline by Stage of Development, 2015
  • IntelGenx Corp. - Monotherapy Products in Pipeline, 2015
  • IntelGenx Corp. - Out-Licensed Products in Pipeline, 2015
  • IntelGenx Corp. - Pipeline by Top 10 Target, 2015
  • IntelGenx Corp. - Pipeline by Top 10 Route of Administration, 2015
  • IntelGenx Corp. - Pipeline by Top 10 Molecule Type, 2015
  • IntelGenx Corp. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top